Evidence map›Paper›PMID 40813711›Full record

Trial reportNature medicine2025

Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial.

Kari L Kendra, Shay L Bellasea, Zeynep Eroglu, Siwen Hu-Lieskovan, Katie M Campbell, William E Carson, David A Wada, Jose A Plaza, Jeffrey A Sosman, Gino K In and 23 more

Erratum issued Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02775851 (A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02775851 phase2active not recruitingnot on this map

A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2017 to 2027Enrolled57ConditionsDesmoplastic MelanomaArmsBiopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography, Pembrolizumab
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors.

Kari L KendraOhio State University Wexner Medical Center, Columbus, OH, USA. kari.kendra@osumc.edu.ORCID http://orcid.org/0000-0001-5936-6689
Shay L BellaseaSWOG Statistics and Data Management Center, Seattle, WA, USA.
Zeynep ErogluH. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Siwen Hu-LieskovanHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Katie M CampbellJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-6491-4432
William E CarsonOhio State University Wexner Medical Center, Columbus, OH, USA.
David A WadaHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Jose A PlazaOhio State University Wexner Medical Center, Columbus, OH, USA.
Jeffrey A SosmanNorthwestern University, Chicago, IL, USA.
Gino K InNorris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Alexandra IkeguchiUniversity of Oklahoma Stephenson Cancer Center, Oklahoma City, OK, USA.ORCID http://orcid.org/0000-0002-4448-9755
John HyngstromHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Andrew S BrohlH. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.ORCID http://orcid.org/0000-0002-0071-0534
Nikhil I KhushalaniH. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Joseph MarkowitzH. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
George NegreaLewis Cancer and Research Pavilion, Savannah, GA, USA.
Samer KasbariSoutheastern Medical Oncology Center, Goldsboro, NC, USA.
Gary C DoolittleUniversity of Kansas Cancer Center, Westwood, KS, USA.
Umang SwamiHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0003-3518-0411
Toni RobertsSaint Michael Cancer Center, Bremerton, WA, USA.
Boban N MathewMasonic Cancer Alliance, Freeman Cancer Center, Pittsburgh, PA, USA.
Egmidio MedinaJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-3284-5329
Ignacio Baselga-CarreteroJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.
Cynthia R GonzalezJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.
Ivan Perez GarcilazoJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.
Agustin Vega-CrespoJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.
Jia Ming ChenJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-3992-9143
Nataly Naser Al-DeenJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.
Sapna P PatelThe University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elad SharonCancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
James MoonSWOG Statistics and Data Management Center, Seattle, WA, USA.
Michael C WuSWOG Statistics and Data Management Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-3357-6570
Antoni RibasJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA. aribas@mednet.ucla.edu.ORCID http://orcid.org/0000-0003-3669-8458

Funding

Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Catherine M. Tangen · 2014 to 2026
$115.2M
Project 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORICEAU, GATIEN P · 2020 to 2024
$12.8M
Next Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4M
OSU as a Network Lead Academic Participating Site for the NCI NCTNUG1CA233331 · NCI · OHIO STATE UNIVERSITY · PI John L. Hays, Dwight H. Owen · 2019 to 2026
$8.9M
NCI NIH HHS P01 CA244118NCI NIH HHS R35 CA197633NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA233331
6 · The paper itself

Abstract

Desmoplastic melanoma is a distinct subtype of melanoma known to have preexisting immune infiltrates and high ultraviolet light damage, resulting in a high tumor mutational burden. We hypothesized that this may result in high response rates with single-agent anti-programmed death protein 1 (PD-1) therapy. SWOG S1512 was a two-cohort clinical trial testing the activity of pembrolizumab in patients with surgically resectable (cohort A) and unresectable (cohort B) desmoplastic melanoma. Here we report on the cohort B single-arm clinical trial, which enrolled 27 patients with unresectable desmoplastic melanoma receiving pembrolizumab 200 mg intravenously every 3 weeks for up to 2 years, with the primary endpoint of complete response rate. The complete response rate was 37% (95% confidence interval: 19-58%), and the post hoc endpoint of objective response rate was 89% (95% confidence interval: 71-98%). The estimated secondary endpoints of 3-year melanoma-specific progression-free survival and overall survival were 84% and 96%, respectively, with only one patient having died from melanoma progression. Ten patients (37%) experienced grade 3 or 4 adverse events, and nine patients (33%) discontinued treatment because of adverse events. Patients with advanced desmoplastic melanoma have a high response rate to single-agent PD-1 blockade therapy, supporting single-agent anti-PD-1 as the treatment of choice, but are limited by a frequency of toxicities that is numerically higher than in other patient populations. ClinicalTrials.gov identifier: NCT02775851.

Indexed as

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsMelanomaProgrammed Cell Death 1 ReceptorSkin NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedProgression-Free SurvivalTreatment OutcomeAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 Receptor

Identifiers

PMID40813711
PMCPMC12419231

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.